Abasaglar ® (insulin glargin)

För fullständig produktresumé för Abasaglar® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Abasaglar® (insulin glargin): Användning hos patienter med bekräftad eller misstänkt COVID-19

Om du har COVID-19 eller tror att du kan ha COVID-19, tala med din läkare. Om du tycker att din medicin ska bytas, kontakta först din läkare eller apotekspersonal.

SE_cFAQ_BIV508_CORONAVIRUS_PATIENTS
cFAQ
cFAQ
SE_cFAQ_BIV508_CORONAVIRUS_PATIENTS
en-GB

Use of Abasaglar when having COVID-19

Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously referred to as "2019 novel coronavirus."1

Eli Lilly and Company has not studied the use of Abasaglar in patients with COVID-19 nor in patients at risk of contracting COVID-19.

Tell your doctor when you have or think you might have COVID-19. Your doctor will help you to manage COVID-19 and to maintain good glyceamic control during infection and recovery.

Talk with your health care provider, pharmacist, or nurse if you have more questions about the use of Abasaglar if you have, or think you might have, COVID-19.

Do NOT stop Abasaglar without speaking to a doctor

If you stop using Abasaglar, this could lead to

  • severe hyperglycaemia (very high blood sugar) and
  • ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar).2

Do not stop Abasaglar without speaking to a doctor, who will tell you what needs to be done.2

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to

References

1Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 27, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2Abasaglar [package leaflet: information for the patient]. Eli Lilly Nederland B.V., The Netherlands.

3Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

4International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html. Accessed March 18, 2020

5COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china

Glossary

ECDC = European Centre for Disease Prevention and Control

EU WHO = World Health Organization (European regional office)

IDF = International Diabetes Federation

Datum fӧr senaste ӧversyn March 27, 2020


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss